CRISPR Therapeutics Dirección
Dirección controles de criterios 3/4
El CEO de CRISPR Therapeutics' es Sam Kulkarni , nombrado en Dec 2017, tiene una permanencia de 6.33 años. compensación anual total es $12.32M, compuesta por 5.9% salario y 94.1% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.48% de las acciones de la empresa, por valor de $23.02M. La antigüedad media del equipo directivo y de la junta directiva es de 5.4 años y 4.8 años, respectivamente.
Información clave
Sam Kulkarni
Chief Executive Officer (CEO)
US$12.3m
Compensación total
| Porcentaje del salario del CEO | 5.9% |
| Permanencia del CEO | 6.3yrs |
| Participación del CEO | 0.5% |
| Permanencia media de la dirección | 5.4yrs |
| Promedio de permanencia en la Junta Directiva | 4.8yrs |
Actualizaciones recientes de la dirección
Recent updates
Crispr Therapeutics: Now Is The Time To Buy
Apr 24Calculating The Intrinsic Value Of CRISPR Therapeutics AG (NASDAQ:CRSP)
Apr 16
Crispr Therapeutics: CASGEVY Commercial Launch Is Taking Shape
Mar 26There's Reason For Concern Over CRISPR Therapeutics AG's (NASDAQ:CRSP) Massive 26% Price Jump
Feb 22Crispr Therapeutics: Cautiously Optimistic
Feb 22Crispr Therapeutics: Investors Bet Against Casgevy Uptake
Feb 01Crispr Therapeutics: Commercial Validation Is The Next Step
Jan 18Impact Of Gene Therapies And Casgevy On Crispr AG And The Industry
Jan 11CRISPR Therapeutics AG's (NASDAQ:CRSP) Popularity With Investors Is Under Threat From Overpricing
Dec 25CRISPR Therapeutics (NASDAQ:CRSP) Is In A Good Position To Deliver On Growth Plans
Nov 02A Look At The Intrinsic Value Of CRISPR Therapeutics AG (NASDAQ:CRSP)
Oct 05CRISPR Therapeutics AG's (NASDAQ:CRSP) Business Is Yet to Catch Up With Its Share Price
Sep 14We're Not Very Worried About CRISPR Therapeutics' (NASDAQ:CRSP) Cash Burn Rate
Jul 24Calculating The Fair Value Of CRISPR Therapeutics AG (NASDAQ:CRSP)
Jun 28CRISPR Therapeutics (NASDAQ:CRSP) Is In A Good Position To Deliver On Growth Plans
Apr 02CRISPR Therapeutics AG's (NASDAQ:CRSP) Intrinsic Value Is Potentially 34% Above Its Share Price
Mar 06Companies Like CRISPR Therapeutics (NASDAQ:CRSP) Are In A Position To Invest In Growth
Dec 08CRISPR CAR T cell therapy for skin/blood cancer gets FDA regenerative medicine tag
Sep 28Crispr: Elucidating And Forecasting Key Developments
Sep 21Crispr Therapeutics: Nearing Harvest Season
Sep 08Crispr Therapeutics: Unlikely To Fall To May Lows, But Not The Time To Buy Yet (Technical Analysis)
Aug 25News Flash: Analysts Just Made A Noticeable Upgrade To Their CRISPR Therapeutics AG (NASDAQ:CRSP) Forecasts
Aug 09CRISPR Therapeutics GAAP EPS of -$2.40 misses by $0.19, revenue of $0.16M misses by $2.04M
Aug 08Crispr Therapeutics' Continued Progress Warrants A Buy
Jul 25Crispr Therapeutics: Innovation Day Showcases Upside Opportunities In Short And Long Term
Jun 23Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Dec 31 2023 | US$12m | US$725k | -US$154m |
| Sep 30 2023 | n/a | n/a | -US$354m |
| Jun 30 2023 | n/a | n/a | -US$416m |
| Mar 31 2023 | n/a | n/a | -US$524m |
| Dec 31 2022 | US$21m | US$700k | -US$650m |
| Sep 30 2022 | n/a | n/a | -US$681m |
| Jun 30 2022 | n/a | n/a | -US$633m |
| Mar 31 2022 | n/a | n/a | US$312m |
| Dec 31 2021 | US$17m | US$670k | US$378m |
| Sep 30 2021 | n/a | n/a | US$412m |
| Jun 30 2021 | n/a | n/a | US$447m |
| Mar 31 2021 | n/a | n/a | -US$392m |
| Dec 31 2020 | US$9m | US$625k | -US$349m |
| Sep 30 2020 | n/a | n/a | -US$211m |
| Jun 30 2020 | n/a | n/a | US$20m |
| Mar 31 2020 | n/a | n/a | US$46m |
| Dec 31 2019 | US$16m | US$550k | US$67m |
| Sep 30 2019 | n/a | n/a | -US$11m |
| Jun 30 2019 | n/a | n/a | -US$200m |
| Mar 31 2019 | n/a | n/a | -US$185m |
| Dec 31 2018 | US$10m | US$518k | -US$165m |
| Sep 30 2018 | n/a | n/a | -US$117m |
| Jun 30 2018 | n/a | n/a | -US$91m |
| Mar 31 2018 | n/a | n/a | -US$75m |
| Dec 31 2017 | US$7m | US$405k | -US$68m |
Compensación vs. Mercado: La compensación total de Sam($USD12.32M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD6.59M).
Compensación vs. Ingresos: La compensación de Sam ha sido consistente con los resultados de la empresa en el último año.
CEO
Sam Kulkarni (45 yo)
6.3yrs
Permanencia
US$12,322,196
Compensación
Dr. Samarth Kulkarni, Ph D., also known as Sam, has been an Independent Director of Repare Therapeutics Inc. since November 2019. Dr. Kulkarni serves as an Independent Non-Executive Director of Centessa Ph...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO & Chairman | 6.3yrs | US$12.32m | 0.48% $ 21.6m | |
| Chief Financial Officer | 1.1yrs | US$5.91m | 0.012% $ 529.9k | |
| General Counsel & Secretary | 6.9yrs | US$3.51m | 0.072% $ 3.2m | |
| Founder | no data | sin datos | sin datos | |
| Co-Founder & Scientific Advisory Board Member | no data | sin datos | sin datos | |
| Scientific Founder & Advisory Board Member | no data | sin datos | sin datos | |
| Scientific Founder | no data | sin datos | sin datos | |
| Scientific Founder & Advisory Board Member | no data | sin datos | sin datos | |
| Scientific Founder & Advisory Board Member | no data | sin datos | sin datos | |
| Head of Technical Operations | 4.5yrs | sin datos | sin datos | |
| Vice President of Corporate Communications & Investor Relations | no data | sin datos | sin datos | |
| Head of Human Resources | no data | sin datos | sin datos |
5.4yrs
Permanencia media
48yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de CRSP es experimentado (5.4 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO & Chairman | 5.8yrs | US$12.32m | 0.48% $ 21.6m | |
| Co-Founder & Scientific Advisory Board Member | no data | sin datos | sin datos | |
| Scientific Founder & Advisory Board Member | no data | sin datos | sin datos | |
| Scientific Founder & Advisory Board Member | no data | sin datos | sin datos | |
| Scientific Founder & Advisory Board Member | no data | sin datos | sin datos | |
| Lead Independent Director | 3.8yrs | US$552.56k | 0.0024% $ 106.2k | |
| Independent Director | 9yrs | US$545.06k | 0.00032% $ 14.4k | |
| Independent Director | 4.8yrs | US$532.56k | 0% $ 0 | |
| Independent Director | 9yrs | US$542.56k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Independent Director | 4.8yrs | US$555.06k | 0% $ 0 | |
| Independent Director | 2.8yrs | US$536.24k | 0% $ 0 |
4.8yrs
Permanencia media
57yo
Promedio de edad
Junta con experiencia: La junta directiva de CRSP se considera experimentada (4.8 años de antigüedad promedio).